GLP-1 drugs have shown neuroprotective effects in lab models, and the review looks at where human clinical evidence stands so far.
Recap by typeshit. Full story at News-Medical.Net.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
He cites FDA counts of 990 adverse event reports tied to compounded semaglutide and over 730 for compounded tirzepatide, and warns about research-use-only sellers.
Trials show no overall rise in cancer with GLP-1 drugs, OncoDaily says, but thyroid cancer is still a watch point and long-term effects remain unclear.
Loading…